Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference [Yahoo! Finance]
Gossamer Bio, Inc. (GOSS)
Last gossamer bio, inc. earnings: 3/24 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024 International Conference, which takes place May 17-22 in San Diego, California. Details for the oral presentation related to seralutinib, an inhaled, PDGFR, CSF1R and c-KIT inhibitor, designed for the treatment of pulmonary hypertension, are as follows: Session: A14: Building Lego(Land): Lessons Learned From Large Scale Clinical Trials In PAH Session Date & Time: Sunday, May 19 th , 9:15 a.m. - 11:15 a.m. PT Talk Title: Interim Results from the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH) Location: San Diego Convention Center, Room 29A-D (Upper Level) Presenting Author: Olivier Sitbon, MD, PhD Gossamer also will present additional data
Show less
Read more
Impact Snapshot
Event Time:
GOSS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOSS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOSS alerts
High impacting Gossamer Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GOSS
News
- Gossamer Bio, Inc. (NASDAQ: GOSS) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $9.00 price target on the stock.MarketBeat
- Gossamer Bio, Inc. (NASDAQ: GOSS) had its "buy" rating re-affirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $8.00 price target on the stock.MarketBeat
- Nimble Announces Formation of a World-Class Scientific Advisory Board [Yahoo! Finance]Yahoo! Finance
- Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Gossamer Bio, Inc. (NASDAQ: GOSS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
GOSS
Earnings
- 11/9/23 - Miss
GOSS
Sec Filings
- 6/25/24 - Form 4
- 6/24/24 - Form 4
- 6/20/24 - Form 4
- GOSS's page on the SEC website